Background: Granzyme B, one of 5 granzymes in humans, is a serine protease primarily produced by cytotoxic T cells and NK cells and released along with perforin to induce apoptosis of target cells. It serves as one of the activation markers for CD8+ memory T cells. Inflammation can also lead to granzyme B production by T helper cells, regulatory T cells, and many cell types of the myeloid lineage. Granzyme B contributes to certain diseases including COPD and asthma.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis of stained tissue microarray using the appropriate positive and negative tissue field of views.

Recommended Usage:Human FFPE: 1.5 ug/mL.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References
Boivin, W.A., Cooper, D.M., Hiebert, P.R., Granville, D.J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Laboratory Investigation. 2009; 89:1195–1220.

* Conjugate tested on human tissue.